How has the 2020/COVID-19 global health crisis led to unprecedented public-private partnerships?

Edition

Moderated roundtable discussion consisting in an exchange of ideas and perspectives by international experts to delve into the latest challenges of the sector.

Panel discussion

How has the 2020/COVID-19 global health crisis led to unprecedented public-private partnerships?

COVID-19 outbreak has shaken the world and the entire life sciences industry has been committed to bring solutions forward in the fight against the pandemic. How have private and public players been joining forces to facilitate research and development? How have pharma, biotech start-ups, medtech companies, academia and public health agencies concretely been working together on diagnostic, treatments, clinical repurposing, and preventive vaccines? What can be taken away from the experimental partnerships and collaborations that have emerged in this global health crisis context?

Reyk Horland

CEO
Germany
TissUse

Rob Smeets

EU Programme Manager
The Netherlands
Philips

Vassilis Georgiadis

Principal, Partnerships (Pharma & Healthcare)
United Kingdom
UCL Innovation and Enterprise

Pierre Meulien

Executive Director
Belgium
Innovative Medicines Initiative

Rafaela Kunz

Open Innovation Consultant, Biotechnologist & IP Expert
Germany
InseaConsulting
  • No products in the cart.